Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Drug Details

Click here to go back to your search results.

Brand Name: Taxol Trade Name: paclitaxel
FDA Approved For: dForTAXOL is indicated, after failure of first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary. TAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. TAXOL is indicated for the second-line treatment of AIDS-related Kaposiís sarcoma. Pediatric Use: The safety and effectiveness of TAXOL in pediatric patients have not been established.
Carcinogen: The carcinogenIc potential of TAXOL has not been studied. Mutagen: Paclitaxel has been shown to be clastogenic in vitro ( chromosome aberrations in human lymphocytes) and in vivo ( micronucleus test in mice). Paclitaxel was not mutagenic in the Ames test or the CHO/ HGPRT gene mutation assay.
Manufacturer and/or Distributor: Bristol-Myers Squibb    

Adverse Reactions:
For a complete list of adverse reactions please click on the link "More Information" for this drug.

E-mail to a Friend More Information


Disclaimer:This site provides excerpts from the product label or professional information brochures for some drugs or information provided by the World Health Organization’s International Agency for Research on Cancer. The full information from these sources is not provided by CancerMonthly. To view the full label or professional information brochure please contact the FDA. A link to the product label or professional information brochure is provided for your convenience, but CancerMonthly is not responsible for the availability of such external sites or resources. In addition, CancerMonthly does not provide medical or any other health care advice, diagnosis or treatment. The site and its services, including the information above, are for informational purposes only and are not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to existing treatment. Do not delay seeking and do not disregard medical advice based on information on this site. Cancer Monthly is solely to be used as an informational resource and should never be used to replace contact with your licensed healthcare provider.